-+ 0.00%
-+ 0.00%
-+ 0.00%

Thyssenkrupp Nucera (XTRA:NCH2) Stock Carries Premium P/S On Thin Profitability

Simply Wall St·08/13/2026 19:27:22
Listen to the news

The market has been in wait and see mode with thyssenkrupp nucera KGaA, keeping the stock at €7.95 after a flat week and mixed three month run. The Q3 earnings headline is not revenue growth or a clean profit story. The focus is on how thin profitability now sits against a premium valuation. The company delivered €145m in quarterly sales and group EBIT close to break even, yet still carries a P/S of 1.9x that stands above both European construction peers and its own loss making track record.

Like the growth story at thyssenkrupp nucera KGaA but uneasy about thin profitability against a relatively rich sales multiple? Take a look at the list of solid balance sheet and fundamentals stocks (429 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): €145 million vs. €184 million (revenue declined 21%)
  • Net Income or Loss (Q3 2026 vs Q3 2025): Break even at €0 million vs. a loss of €2 million (shifted from loss to roughly flat)
  • Basic EPS (Q3 2026 vs Q3 2025): Data for Q3 2026 not disclosed vs. a loss of €0.015873 per share in Q3 2025 (no direct comparison possible for this quarter)
  • Group EBIT Margin (Q3 2026 vs Q3 2025): EBIT around break even at approximately €0 million on €145 million of revenue vs. roughly negative margin on €184 million of revenue in Q3 2025, indicating profitability is now sitting close to zero on a smaller sales base.

Prefer clean visuals over scrolling through dense earnings tables and raw figures for thyssenkrupp nucera KGaA? See the full financial picture, including a clear snapshot of its valuation, in the company report for thyssenkrupp nucera KGaA.

XTRA:NCH2 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
XTRA:NCH2 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Thyssenkrupp Nucera bull case meets mixed execution

Bulls argue thyssenkrupp nucera is building a leading green hydrogen platform with improving visibility and a shift toward higher quality revenue. Q3 gives some support. Backlog stands at €638m and 9 month order intake nearly doubled to €471m, helped by the Moeve 300 MW contract and solid Chlor Alkali wins. Paid engineering work of about 1.9 GW plus 3.5 GW under execution backs the idea that FEED and early phase work can convert into larger projects. The first long term green hydrogen service deal, roughly €12m over 8 years, is small but proves the service model that bulls expect to support margins over time. However, green hydrogen sales in Q3 fell to €36m while segment EBIT moved further into loss. That shows the platform is still in heavy build out mode rather than clear earnings delivery.

Bear case on volatility and profit risk still in play

Bears focus on project timing risk, green hydrogen losses and order concentration. Q3 results support several of these concerns. Group sales for the quarter were €145m while 9 month sales were €354m, both weighed by lower green hydrogen revenue as reference projects matured. Green hydrogen EBIT in Q3 moved further into loss at €17m while Chlor Alkali carried group profitability with €50m of EBIT. Updated guidance points to group EBIT between a loss of €105m and €75m for the year, with green hydrogen EBIT expected between a loss of €155m and €135m, plus an additional €30m EBIT hit from the SOEC decision. Order intake guidance was trimmed on the upper end, which fits the worry that some projects slip or resize. Free cash flow was still negative over 9 months, so cash discipline remains an ongoing test.

With Q3 free cash flow still negative, unresolved green hydrogen losses, and a premium 1.9x P/S, it is worth stress testing whether thyssenkrupp nucera KGaA has enough balance sheet strength to see this through. Verify the cash runway, debt profile, and dilution risk in the financial health analysis of thyssenkrupp nucera KGaA stock.

Stay Ahead With Simply Wall St

If the mix of thin profitability, premium P/S and green hydrogen build out at thyssenkrupp nucera KGaA has your interest, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis develops. Once you own shares, use the Portfolio Command Center to cut through noise and focus on the key valuation, earnings and risk updates that matter. For a broader view on sentiment and potential catalysts, tap into thousands of perspectives through the Community. This helps you identify possible catalysts and risks early so you can stay ahead of the market.

Seeking Alternatives Beyond Thyssenkrupp Nucera

Fresh ideas can move fast. Some stocks are building momentum while they are still under the radar for now and others are dropping out of favor. Consider researching them early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.